Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Agios Pharmaceuticals: Clinical Trials & FDA Approval Profile

Agios Pharmaceuticals (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 12 active protocols (3 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.3%
Median Closed Enrollment vs National (145 pts)80 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Agios Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)12 (3)
Completed vs Stopped Early3 / 1 (6.3%)
Median Closed Actual Enrollment80 participants
Physical Hospital Site Disclosure99.8% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Agios Pharmaceuticals
Hospital Research SiteLocationShared Protocols
Universitair Medisch Centrum UtrechtUtrecht8
Emory Winship Cancer InstituteAtlanta, GA8
Massachusetts General HospitalBoston, MA6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Agios Pharmaceuticals
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05031780A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)Phase II/IIIACTIVE NOT RECRUITING
NCT04770753A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NPhase IIIACTIVE NOT RECRUITING
NCT05490446A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)Phase IIACTIVE NOT RECRUITING
NCT03559699A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)Phase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Agios Pharmaceuticals Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI